scholarly article | Q13442814 |
P50 | author | Maximilian Zeyda | Q42753156 |
P2093 | author name string | Georg A Böhmig | |
Walter H Hörl | |||
Gerhard J Zlabinger | |||
Marcus D Säemann | |||
Thomas Baumruker | |||
Ernst Kriehuber | |||
Peter Kelemen | |||
Christos Diakos | |||
P2860 | cites work | CD40 AND CD154 IN CELL-MEDIATED IMMUNITY | Q22255634 |
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation | Q24677534 | ||
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products | Q24678867 | ||
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha | Q28251443 | ||
Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin | Q28568866 | ||
Immunobiology of dendritic cells | Q29547465 | ||
Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts | Q32133064 | ||
Cytokine receptor signaling pathways | Q33916985 | ||
Dendritic cells and prospects for transplantation tolerance | Q34046816 | ||
Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model | Q34159335 | ||
Dendritic cells in transplantation--friend or foe? | Q34241103 | ||
Designer dendritic cells for tolerance induction: guided not misguided missiles | Q34319943 | ||
What's in the pipeline? New immunosuppressive drugs in transplantation | Q35025829 | ||
Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids | Q35209017 | ||
Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection | Q35939463 | ||
Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. | Q36417432 | ||
Jaks and Stats in signaling by the cytokine receptor superfamily | Q40506662 | ||
The role of Jak3 in lymphoid development, activation, and signaling | Q41587141 | ||
Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice | Q44410698 | ||
JAK/STAT signaling by cytokine receptors | Q46606420 | ||
Cutting Edge: Anti-CD154 Therapeutic Antibodies Induce Infectious Transplantation Tolerance | Q61651670 | ||
CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway | Q73509859 | ||
Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival | Q74015557 | ||
Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model | Q74097996 | ||
Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice | Q74420476 | ||
CD40 triggered human monocyte-derived dendritic cells convert to tolerogenic dendritic cells when JAK3 activity is inhibited | Q74604829 | ||
Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway | Q77167696 | ||
Targeting Jak3 for immune suppression and allograft acceptance | Q77369733 | ||
Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates | Q77890140 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | dendritic cell | Q506253 |
P304 | page(s) | 1341-1349 | |
P577 | publication date | 2003-11-01 | |
P1433 | published in | American Journal of Transplantation | Q4744273 |
P1476 | title | Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3. | |
P478 | volume | 3 |
Q35825869 | A new modality for immunosuppression: targeting the JAK/STAT pathway |
Q35994891 | Activation of the Jak3 pathway and myeloid differentiation |
Q37386167 | Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo |
Q64913188 | B Cell-Based Cancer Immunotherapy. |
Q33732210 | CD40 signaling to the rescue: A CD8 exhaustion perspective in chronic infectious diseases |
Q36339318 | CD40/CD154 blockade inhibits dendritic cell expression of inflammatory cytokines but not costimulatory molecules |
Q35953521 | Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis |
Q37438637 | Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis |
Q35636761 | Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis |
Q28586242 | Jak3 negatively regulates dendritic-cell cytokine production and survival |
Q35887829 | Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation |
Q35031161 | Janus kinase-3 dependent inflammatory responses in allergic asthma |
Q37474929 | Molecular mechanism and function of CD40/CD40L engagement in the immune system. |
Q39738927 | Osteopontin affects macrophage polarization promoting endocytic but not inflammatory properties. |
Q28315036 | Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome |
Q36881600 | Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1. |
Search more.